ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer
SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).
- SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).
- Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall corporate strategy planning and implementation.
- Dr. Kong holds a doctor's degree from Shanghai Medical College of Fudan University and a master's degree of Science in Molecular Immunology from University of Nebraska Medical Center.
- Before joining ImmVira, he served as Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, Vice President of Clinical Oncology at Hengrui Therapeutics, Senior Global Medical Leader of Global Medical Affairs at Novartis Oncology, Senior Medical Director at Celegene and Medical Director of US Medical Affairs at Bayer HealthCare Pharmaceuticals.